Cover Image
市場調查報告書

鼻咽炎(感冒):開發平台分析

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229834
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
鼻咽炎(感冒):開發平台分析 Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 35 Pages
簡介

鼻咽炎的特徵是伴隨發燒的鼻炎·咽頭炎。是幼兒常見的疾病。由於是因病毒感染而發病,在治療和化學性預防階段一般不需要抗菌劑。可用退燒藥(兒童非阿斯匹林性藥物)來退燒。

本報告提供全球各國治療鼻咽炎(感冒)用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查。

簡介

  • 分析範圍

鼻咽炎概要

治療藥的開發

  • 鼻咽炎開發中產品:概要
  • 鼻咽炎開發中產品:比較分析

各企業正在開發的鼻咽炎治療藥

大學/研究機關研究中的鼻咽炎治療藥

開發中產品的概要

  • 初期階段的產品
  • 不明確階段的產品

鼻咽炎治療藥:開發中的產品一覽(各企業)

鼻咽炎治療藥:研究中的產品一覽(大學/研究機關別)

鼻咽炎開發治療藥的企業

  • Charleston Laboratories, Inc.
  • Cocrystal Pharma, Inc.
  • Neos Therapeutics, Inc.
  • Orbis Biosciences, Inc.
  • Vernalis Plc

鼻咽炎:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (馬來酸kurorufeniramin + kodein)
  • TRIM-21為目標的消化器官疾病/耳鼻咽疾病抗體
  • CCP-05
  • CCP-06
  • CCP-07
  • CCP-08
  • CLAT-313
  • guaifeneshin ER
  • 咳嗽/感冒小分子
  • 針對氣喘/感冒的MAPK13抑制分子
  • 一般感冒用RNA依賴性RNA聚合酵素抑制分子

鼻咽炎治療藥:最新的藥物簡介

鼻咽炎治療藥:開發暫停的產品

鼻咽炎治療藥:開發中止的產品

鼻咽炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8961IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape.

Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration and Preclinical stages are 2 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nasopharyngitis (Common Cold) - Overview
  • Nasopharyngitis (Common Cold) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Nasopharyngitis (Common Cold) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
    • Charleston Laboratories Inc
    • Orbis Biosciences Inc
    • Vernalis Plc
  • Nasopharyngitis (Common Cold) - Drug Profiles
    • Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLAT-313 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • guaifenesin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORB-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nasopharyngitis (Common Cold) - Dormant Projects
  • Nasopharyngitis (Common Cold) - Discontinued Products
  • Nasopharyngitis (Common Cold) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 06, 2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review
      • Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
      • Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
      • Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
      • Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
      • Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
      • Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
      • Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nasopharyngitis (Common Cold), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories Inc, H1 2017
  • Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences Inc, H1 2017
  • Nasopharyngitis (Common Cold) - Pipeline by Vernalis Plc, H1 2017
  • Nasopharyngitis (Common Cold) - Dormant Projects, H1 2017
  • Nasopharyngitis (Common Cold) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Nasopharyngitis (Common Cold), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top